Physician profile
Bryan M Kim
NPI 1326215039
$7,651.62
in general payments reported to CMS, 2019-2025
16 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $105 · 2021: $1,791 · 2022: $2,028 · 2023: $525 · 2024: $2,322 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.47 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $5,218.57 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $607.68 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $373.89 | 2019-2025 | Vabysmo |
| Abbvie INC. | $329.30 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $213.42 | 2023-2025 | Syfovre |
| Alimera Sciences, INC. | $188.60 | 2020-2024 | Iluvien, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $169.68 | 2019 | |
| Ani Pharmaceuticals, INC. | $122.82 | 2025 | Iluvien, Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $116.81 | 2021-2024 | Acthar |
| Allergan, INC. | $71.16 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $63.46 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $52.63 | 2019 | |
| Spark Therapeutics, INC. | $41.61 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $38.86 | 2022 | |
| Coherus Oncology, INC. | $22.89 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $20.24 | 2025 | Lumera 700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.